We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+15.31%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$51.8M
AUM Growth
+$4.44M
Cap. Flow
-$659K
Cap. Flow %
-1.27%
Top 10 Hldgs %
97.02%
Holding
55
New
45
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$5.02M
2
GSK icon
GSK
GSK
+$5M
3
CAH icon
Cardinal Health
CAH
+$2.28M
4
UTMD icon
Utah Medical Products
UTMD
+$730K
5
UNH icon
UnitedHealth
UNH
+$201K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$4.42M
2
GILD icon
Gilead Sciences
GILD
+$3.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.49M
4
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$2.26M
5
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPRX icon
26
Royalty Pharma
RPRX
$25.7B
$31.3K 0.06%
+791
New +$33K
EW icon
27
Edwards Lifesciences
EW
$54B
$26.6K 0.05%
+356
New +$27.4K
MASI
28
DELISTED
Masimo
MASI
$22.5K 0.04%
+152
New +$20.9K
NBIX icon
29
Neurocrine Biosciences
NBIX
$16.5B
$22.2K 0.04%
+186
New +$21.8K
OPCH icon
30
Option Care Health
OPCH
$3.61B
$22.1K 0.04%
+736
New +$22.8K
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$29.6B
$22.1K 0.04%
+93
New +$19.8K
CYTK icon
32
Cytokinetics
CYTK
$10.6B
$20.2K 0.04%
+440
New +$18.9K
DOCS icon
33
Doximity
DOCS
$4.65B
$15.5K 0.03%
+462
New +$14.1K
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.5K 0.03%
+292
New +$14.6K
RXDX
35
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$13.4K 0.03%
+122
New +$7.91K
EXAS
36
DELISTED
Exact Sciences
EXAS
$13.3K 0.03%
+268
New +$10.9K
INSP icon
37
Inspire Medical Systems
INSP
$1.71B
$13.1K 0.03%
+52
New +$11.1K
KRYS icon
38
Krystal Biotech
KRYS
$9.68B
$11K 0.02%
+139
New +$10.3K
AKRO
39
DELISTED
Akero Therapeutics
AKRO
$9.1K 0.02%
+166
New +$7.11K
OM icon
40
Outset Medical
OM
$90.6M
$8.88K 0.02%
+23
New +$6.49K
BLU
41
DELISTED
BELLUS Health Inc.
BLU
$8.84K 0.02%
+1,075
New +$10K
PRTA icon
42
Prothena Corp
PRTA
$473M
$7.89K 0.02%
+131
New +$7.67K
MRVI icon
43
Maravai LifeSciences
MRVI
$866M
$6.8K 0.01%
+475
New +$7.48K
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
$6.76K 0.01%
+554
New +$6.24K
BBIO icon
45
BridgeBio Pharma
BBIO
$16.4B
$6.76K 0.01%
+887
New +$8.49K
BCYC
46
Bicycle Therapeutics
BCYC
$288M
$6.69K 0.01%
+226
New +$6.06K
KRTX
47
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.68K 0.01%
+34
New +$7.29K
SWAV
48
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$6.58K 0.01%
+32
New +$8.09K
IMGN
49
DELISTED
Immunogen Inc
IMGN
$6.45K 0.01%
+1,300
New +$7.05K
PSTX
50
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.67K 0.01%
+1,069
New +$4.89K
1
2
3

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

HealthInvest Partners's Q4 2022 Portfolio in Review

As of Q4 2022, HealthInvest Partners held 55 positions worth $51.8M, up 9.4% from $47.3M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

HealthInvest Partners's Q4 2022 filing shows 45 new, 2 increased, 5 reduced and 2 closed positions. Its largest new stake was CVS Health: 52,000 shares worth $4.85M. The largest sale was McKesson, an estimated $4.42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q4 2022 buy was CVS Health: 52,000 shares worth $4.85M.
  • HealthInvest Partners added most to Cardinal Health in Q4 2022, an estimated $2.28M increase.
  • HealthInvest Partners's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $3.5M.
  • HealthInvest Partners fully exited McKesson in Q4 2022, selling an estimated $4.42M.
  • HealthInvest Partners's ten largest holdings make up 97% of its $51.8M portfolio in Q4 2022.
  • HealthInvest Partners opened 45 new positions and closed 2 in Q4 2022.
  • HealthInvest Partners's portfolio value rose 9.4% quarter-over-quarter to $51.8M.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.